Healios KK (JP:4593)
:4593
Want to see JP:4593 full AI Analyst Report?
Top Page
Healios KK
(4593)
Select Model
Select Model
Rating:43Neutral
Price Target:
¥245.00
▼(-33.78% Downside)
Action:Reiterated
Date:06/11/26
The score is driven primarily by weak financial performance (large losses, falling revenue, and substantial cash burn) and a bearish technical setup (price below major moving averages with negative MACD). Valuation offers limited support due to negative earnings and no dividend yield data.
Positive Factors
Improved balance sheet resilience
Lower leverage and a materially larger equity base provide a more durable capital cushion versus prior years. This reduces near-term refinancing risk and gives management flexibility to fund clinical programs or negotiate partnerships without immediate debt pressure, supporting multi-quarter R&D continuity.
Negative Factors
Heavy cash burn
Substantial negative operating and free cash flow indicate the business is consuming cash faster than it generates it, creating persistent funding needs. Over the medium term this increases reliance on dilutive financing, licensing deals, or asset sales, which can impair shareholder value if not addressed.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved balance sheet resilience
Lower leverage and a materially larger equity base provide a more durable capital cushion versus prior years. This reduces near-term refinancing risk and gives management flexibility to fund clinical programs or negotiate partnerships without immediate debt pressure, supporting multi-quarter R&D continuity.
Read all positive factors
Healios KK (4593) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥35.24B
Dividend YieldN/A
Average Volume (3M)1.65M
Price to Earnings (P/E)―
Beta (1Y)1.15
Revenue Growth-87.41%
EPS Growth43.60%
CountryJP
Employees65
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-24.18
Shares Outstanding135,002,200
10 Day Avg. Volume1,843,110
30 Day Avg. Volume1,654,023
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)6.03
Price to Sales (P/S)283.63
P/FCF Ratio-8.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥965.00Price Target Upside160.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-35.24
Revenue Forecast (FY)¥402.20M
Healios KK Business Overview & Revenue Model
Company Description
Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key markets in...
How the Company Makes Money
Healios’ primary economic model is typical of a development-stage biotech company: it seeks to create value through progressing cell-therapy/regenerative-medicine candidates through research and clinical development, with monetization generally oc...
Healios KK Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 74.00M | 104.00M | 560.00M | 121.00M | 90.00M | 41.00M |
| Gross Profit | -392.00M | -389.00M | 432.00M | 108.00M | 90.00M | 41.00M |
| EBITDA | -1.91B | -3.13B | -2.54B | -3.16B | -4.52B | -3.61B |
| Net Income | -3.13B | -2.22B | -4.24B | -3.82B | -5.17B | -4.91B |
Balance Sheet | ||||||
| Total Assets | 23.48B | 17.05B | 14.19B | 15.15B | 15.03B | 23.97B |
| Cash, Cash Equivalents and Short-Term Investments | 10.87B | 5.68B | 3.67B | 6.72B | 7.25B | 15.13B |
| Total Debt | 2.59B | 2.61B | 2.66B | 4.53B | 7.15B | 11.96B |
| Total Liabilities | 15.91B | 12.15B | 12.11B | 11.29B | 10.65B | 15.33B |
| Stockholders Equity | 7.55B | 4.89B | 2.06B | 3.86B | 4.38B | 8.64B |
Cash Flow | ||||||
| Free Cash Flow | -3.87B | -3.33B | -1.83B | -2.85B | -4.86B | -5.39B |
| Operating Cash Flow | -3.67B | -3.17B | -1.82B | -2.82B | -4.60B | -5.09B |
| Investing Cash Flow | -1.55B | -1.11B | -1.42B | -1.12B | -909.00M | -736.00M |
| Financing Cash Flow | 10.60B | 6.33B | 77.00M | 3.34B | -2.50B | 6.99B |
Healios KK Technical Analysis
Negative
370.00
Price Trends
339.34
Negative
362.16
Negative
410.67
Negative
Market Momentum
-21.04
Positive
30.56
Neutral
18.80
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4593, the sentiment is Negative. The current price of 370 is above the 20-day moving average (MA) of 309.05, above the 50-day MA of 339.34, and below the 200-day MA of 410.67, indicating a bearish trend. The MACD of -21.04 indicates Positive momentum. The RSI at 30.56 is Neutral, neither overbought nor oversold. The STOCH value of 18.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4593.
Healios KK Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥23.72B | -32.28 | ― | ― | -11.11% | -187.80% | |
45 Neutral | ¥17.93B | -9.59 | ― | ― | ― | 6.10% | |
43 Neutral | ¥35.24B | -10.48 | ― | ― | -87.41% | 43.60% | |
42 Neutral | ¥93.75B | -23.82 | -253.07% | ― | ― | -25.72% | |
42 Neutral | ¥12.08B | -20.34 | ― | ― | -25.02% | -697.06% | |
42 Neutral | ¥8.34B | -8.15 | ― | ― | -62.06% | 7.56% |
* Healthcare Sector Average
JP:4593
Healios KK
261.00
-280.00
-51.76%
JP:4592
SanBio Co
1,201.00
-2,019.00
-62.70%
JP:4599
StemRIM Inc.
286.00
-69.00
-19.44%
JP:4978
ReproCELL Inc.
127.00
-65.00
-33.85%
JP:7774
Japan Tissue Engineering Co., Ltd.
584.00
-27.00
-4.42%
JP:7776
CellSeed Inc.
213.00
-302.00
-58.64%
Healios KK Corporate Events
Healios Files Counterclaim in Payment Dispute with AND Medical
Jun 9, 2026
Healios K.K. has filed a counterclaim in the Tokyo District Court against its joint research partner AND medical group, seeking ¥66 million plus delay damages over an unpaid final milestone in a cultured supernatant development agreement. The...
Healios Highlights Uncertainty Around FY2026 Q1 Disclosures and Outlook
May 14, 2026
Healios K.K. released materials related to its fiscal 2026 first-quarter financial results, accompanied by extensive cautionary language on the limitations and risks of forward-looking statements. The company emphasized that its disclosures are ba...
Healios Signs ¥144 Million Stem Cell Supernatant Supply Deal With JENECELL
Apr 7, 2026
Healios K.K. has agreed to supply human bone marrow-derived somatic stem cell culture supernatant as a raw material for future cosmetics products to be marketed in South Korea by JENECELL, a South Korean subsidiary of Alfresa Corporation. The init...
Healios Wins ¥7 Billion METI Subsidy to Build Regenerative Medicine CDMO Hub in Kobe
Mar 27, 2026
Healios K.K., a leading Japanese regenerative medicine biotech, is expanding its cell and gene therapy capabilities across somatic stem cell and iPSC platforms, with late-stage clinical experience for its MAPC-based invimestrocel therapy and precl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.